A Phase 1a/1 b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 in Combination with AK104 in Subjects with Advanced or Metastatic Solid Tumors

  • Body, Amy (Primary Chief Investigator (PCI))
  • Frentzas, Sophia (Chief Investigator (CI))

Project: Research

Project Details

Effective start/end date19/02/2118/02/26


  • clinical trial
  • treatment safety
  • treatment efficacy
  • solid tumours